Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI ) Market, by Drug Type (Oral & Parenteral Antibiotics (Oritavancin, Delafloxacin, Vancomycin, Daptomycin, Dalbavancin, Ceftaroline, Linezolid, Tedizolid, Clindamycin, and Others (Rifampin, Doxycycline, Minocycline, Trimethoprim-Sulfa Methoxazol, etc.)) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,466.6 Million in 2022 and is expected to exhibit a CAGR of 6.0% during the forecast period (2022-2030).

Market players are involved in launching new products, which is expected to drive growth of the global acute bacterial skin and skin structure infections market, over the forecast period. For instance, on January 17, 2022, Paladin Labs Inc., a pharmaceutical company, launched Xydalba (dalbavancin), a 30-minute intravenous therapy for acute bacterial skin and skin structure infections that can be administered as a single- or two-dose regimen.

In addition, market players are engaged in research and development activities for development of new drugs in the treatment global acute bacterial skin and skin structure infections. This is expected to drive growth of the global acute bacterial skin and skin structure infections market, over the forecast period. For instance, on March 29, 2019, Allergan, Inc., a pharmaceutical company, completed phase IV clinical trial for Dalbavancin to evaluate a new critical pathway for treatment of patients with acute bacterial skin and skin structure infections. Dalbavancin is a semisynthetic lipoglycopeptide, used in the treatment of skin infections caused by definite types of bacteria such as methicillin-resistant Staphylococcus aureus.

Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus (COVID-19) pandemic is expected to hamper growth of the global acute bacterial skin and skin structure infections over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the update by World Health Organization (WHO) on COVID-19, after August 3, 2022 the number of new cases are increasing. Therefore, as of August 3, 2022, around 578 million cases and over 6.4 million deaths have been reported globally.

Decline in clinical trials for new drugs during COVID-19 pandemic is expected to hamper the growth of global acute bacterial skin and skin structure infections market. For instance, according to published data September 30, 2020, by National Institute of Health, U.S., and World Health Organization has stated more than 31,186,000 confirmed cases of COVID-19, including 962,343 deaths, worldwide as on September 21, 2020. Due to need for developing new vaccines to treat COVID-19, many forthcoming and ongoing clinical trials for other diseases was stopped globally. The disruption of clinical trials for all kind of drugs is expected to hamper growth of the global acute bacterial skin and skin structure infections market during COVID-19 pandemic.

 Browse 44 Market Data Tables and 59 Figures spread through 426 Pages and in-depth TOC on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI ) Market, by Drug Type (Oral & Parenteral Antibiotics (Oritavancin, Delafloxacin, Vancomycin, Daptomycin, Dalbavancin, Ceftaroline, Linezolid, Tedizolid, Clindamycin, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, etc)) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the Global Acute Bacterial Skin and Skin Structure Infections market, click the link below:

https://www.coherentmarketinsights.com/market-insight/acute-bacterial-skin-and-skin-structure-infections-absssi-market-1531

Key players are involved in the launching of new products and this is expected to drive growth of the acute bacterial skin and skin structure infections market. For instance, in September, 2020, Cipla, a pharmaceutical company launched Daptomycin for Injection. Daptomycin is available in 500 mg/vial, used for single dose. Daptomycin for injection is designated for the treatment of adult patients and pediatric patients with complicated skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus.

Key Takeaways of the Global Acute Bacterial Skin and Skin Structure Infections Market:

  • The global acute bacterial skin and skin structure infections market is expected to exhibit a CAGR of 6.0% over the forecast period (2022-2030), owing to growth in potential markets, especially in Europe. While North America accounted for the major market share.
  • Market players are engaged in signing agreement with other key players, in order to expand their product portfolio, which is expected to drive growth of the global acute bacterial skin and skin structure infections market. For instance, in May, 2019, Civica Rx, a drug company, entered an agreement with a Danish, a drugmaker, for making availability of injected forms of antibiotics vancomycin and daptomycin. These antibiotics are used to treat infections caused by antimicrobial-resistant bacterial such as methicillin-resistant Staphylococcus aureus. Methicillin-resistant Staphylococcus aureus is one of the pathogens, which is responsible for causing acute bacterial skin and skin structure infections.
  • Major players operating in the global acute bacterial skin and skin structure infections market include Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd.,  Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.,  

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo